We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+39.61%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$616M
AUM Growth
-$496M
Cap. Flow
-$674M
Cap. Flow %
-109.52%
Top 10 Hldgs %
58%
Holding
48
New
14
Increased
3
Reduced
16
Closed
15

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$25.5M
2
PODD icon
Insulet
PODD
+$14.9M
3
TBPH icon
Theravance Biopharma
TBPH
+$14.8M
4
OCUL icon
Ocular Therapeutix
OCUL
+$12.7M
5
MRSN
Mersana Therapeutics
MRSN
+$10.8M

Top Sells

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$117M
2
SAGE
Sage Therapeutics
SAGE
+$111M
3
UTHR icon
United Therapeutics
UTHR
+$64.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$59.6M
5
CYTK icon
Cytokinetics
CYTK
+$55.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GWPH
1
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$45M 7.31%
390,000
-130,232
-25% -$14.6M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$1.82B
$42.6M 6.91%
917,427
-2,959,173
-76% -$117M
SAGE
3
DELISTED
Sage Therapeutics
SAGE
$39.3M 6.39%
454,417
-1,512,271
-77% -$111M
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.43B
$38.5M 6.26%
720,502
-1,201,061
-63% -$59.6M
RCKT icon
5
Rocket Pharmaceuticals
RCKT
$340M
$38.4M 6.24%
+700,000
New +$25.5M
ZYME icon
6
Zymeworks
ZYME
$1.61B
$37.8M 6.14%
799,722
-768,178
-49% -$35.7M
XENT
7
DELISTED
Intersect ENT, Inc
XENT
$29.8M 4.85%
1,302,871
+554,945
+74% +$10.6M
CNST
8
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$29.5M 4.79%
1,024,800
-1,837,124
-64% -$46.2M
MGNX icon
9
MacroGenics
MGNX
$235M
$28.3M 4.6%
1,239,287
-270,928
-18% -$6.24M
VCEL icon
10
Vericel Corp
VCEL
$2.35B
$27.8M 4.51%
900,000
-580,787
-39% -$13.8M
ARNA
11
DELISTED
Arena Pharmaceuticals Inc
ARNA
$26.5M 4.31%
345,120
-651,778
-65% -$48.9M
GBT
12
DELISTED
Global Blood Therapeutics, Inc.
GBT
$25.8M 4.19%
595,473
-60,203
-9% -$2.97M
UTHR icon
13
United Therapeutics
UTHR
$25.8B
$22.8M 3.7%
150,000
-490,773
-77% -$64.4M
OCUL icon
14
Ocular Therapeutix
OCUL
$1.79B
$17.7M 2.88%
+856,162
New +$12.7M
KDMN
15
DELISTED
Kadmon Holdings, Inc.
KDMN
$16.9M 2.75%
4,083,909
+1,583,909
+63% +$6.25M
PODD icon
16
Insulet
PODD
$11.5B
$15.3M 2.49%
+60,000
New +$14.9M
TBPH icon
17
Theravance Biopharma
TBPH
$874M
$14.7M 2.38%
+824,580
New +$14.8M
ARVN icon
18
Arvinas
ARVN
$518M
$13.9M 2.26%
+164,150
New +$5.66M
PBYI icon
19
Puma Biotechnology
PBYI
$404M
$13.3M 2.17%
1,300,000
+197,927
+18% +$2M
MRSN
20
DELISTED
Mersana Therapeutics
MRSN
$13M 2.11%
+19,498
New +$10.8M
PRTA icon
21
Prothena Corp
PRTA
$425M
$11.7M 1.91%
977,647
-570,832
-37% -$6.75M
EXEL icon
22
Exelixis
EXEL
$13.3B
$9.53M 1.55%
+475,000
New +$9.94M
CALA
23
DELISTED
Calithera Biosciences, Inc
CALA
$9.06M 1.47%
92,250
-53,679
-37% -$4.7M
COLL icon
24
Collegium Pharmaceutical
COLL
$1.15B
$8.44M 1.37%
+421,383
New +$8.23M
FMTX
25
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$8.25M 1.34%
+236,400
New +$10.3M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Great Point Partners held 48 positions worth $616M, down 45% from $1.11B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Great Point Partners withdrew a net $674M in Q4 2020, closing 15 positions and reducing 16 holdings. Its most notable exit was Cytokinetics, an estimated $55.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Rocket Pharmaceuticals worth $38.4M.

  • Great Point Partners's largest Q4 2020 buy was Rocket Pharmaceuticals: 700,000 shares worth $38.4M.
  • Great Point Partners added most to Intersect ENT, Inc in Q4 2020, an estimated $10.6M increase.
  • Great Point Partners's biggest Q4 2020 reduction was Iovance Biotherapeutics, cutting an estimated $117M.
  • Great Point Partners fully exited Cytokinetics in Q4 2020, selling an estimated $55.2M.
  • Great Point Partners's ten largest holdings make up 58% of its $616M portfolio in Q4 2020.
  • Great Point Partners opened 14 new positions and closed 15 in Q4 2020.
  • Great Point Partners's portfolio value fell 45% quarter-over-quarter to $616M.

Based on Great Point Partners's 13F filing for Q4 2020, filed 16 Feb 2021.